Loading…
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $4.1B | $1.0B | $375M | $434M | 4.6% | 5.1% | -4.4% |
| 2024 | $3.9B | $1.1B | $392M | $288M | 4.9% | 8.4% | 33.3% |
| 2023 | $3.6B | $886M | $294M | $215M | 3.9% | 8.6% | -23.7% |
| 2022 | $3.3B | $879M | $386M | $450M | 5.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 3,308.40 | 3,593.20 | 3,895.40 | 4,092.40 |
| Operating Revenue | - | 3,308.40 | 3,593.20 | 3,895.40 | 4,092.40 |
| Cost Of Revenue | - | 1,168.80 | 1,235.30 | 1,299.70 | 1,410.30 |
| Gross Profit | - | 2,139.60 | 2,357.90 | 2,595.70 | 2,682.10 |
| Operating Expense | - | 1,632 | 1,824.80 | 1,890 | 1,999.20 |
| Research And Development | - | 110.30 | 137.40 | 155.10 | 172.20 |
| Selling General And Administration | - | 1,342.20 | 1,501.20 | 1,533.70 | 1,627.80 |
| Total Expenses | - | 2,800.80 | 3,060.10 | 3,189.70 | 3,409.50 |
| Operating Income | - | 507.60 | 533.10 | 705.70 | 682.90 |
| Total Operating Income As Reported | - | 507.60 | 533.10 | 705.70 | 682.90 |
| EBITDA | - | 878.70 | 885.90 | 1,071.70 | 1,043.90 |
| Normalized EBITDA | - | 878.70 | 885.90 | 1,076.90 | 1,051.90 |
| EBIT | - | 532.60 | 518.20 | 696.60 | 666.50 |
| Interest Expense | - | 57.30 | 105.30 | 114.30 | 100 |
| Net Interest Income | - | -57.30 | -105.30 | -114.30 | -100 |
| Other Non Operating Income Expenses | - | 25 | -14.90 | -3.90 | -8.40 |
| Other Income Expense | - | 25 | -14.90 | -9.10 | -16.40 |
| Interest Expense Non Operating | - | 57.30 | 105.30 | 114.30 | 100 |
| Net Non Operating Interest Income Expense | - | -57.30 | -105.30 | -114.30 | -100 |
| Pretax Income | - | 475.30 | 412.90 | 582.30 | 566.50 |
| Tax Provision | - | 89.50 | 118.70 | 190 | 191.60 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -1.70 | -2.70 |
| Net Income Continuous Operations | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income From Continuing And Discontinued Operation | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income From Continuing Operation Net Minority Interest | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income Common Stockholders | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Net Income Including Noncontrolling Interests | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Normalized Income | - | 385.80 | 294.20 | 395.80 | 380.20 |
| Diluted NI Availto Com Stockholders | - | 385.80 | 294.20 | 392.30 | 374.90 |
| Basic Average Shares | - | 197.20 | 198.10 | 199.60 | 195.90 |
| Diluted Average Shares | - | 198.80 | 199.20 | 200.40 | 200 |
| Reconciled Depreciation | - | 346.10 | 367.70 | 375.10 | 377.40 |
| Reconciled Cost Of Revenue | - | 1,002.20 | 1,053.80 | 1,125.80 | 1,232.10 |
| Total Unusual Items | - | 25.70 | -7 | -5.20 | -8 |
| Total Unusual Items Excluding Goodwill | - | 25.70 | -7 | -5.20 | -8 |
| Special Income Charges | 0 | - | - | - | - |
| Impairment Of Capital Assets | 0 | - | - | - | - |
| Gain On Sale Of Security | - | 25.70 | -7 | -5.20 | -8 |
| Depreciation Amortization Depletion Income Statement | - | 179.50 | 186.20 | 201.20 | 199.20 |
| Depreciation And Amortization In Income Statement | - | 179.50 | 186.20 | 201.20 | 199.20 |
| General And Administrative Expense | 1,211.20 | - | - | - | - |
| Other Gand A | 1,211.20 | - | - | - | - |
| Gain On Sale Of Ppe | 0 | - | - | - | - |
| Earnings From Equity Interest | 11.60 | - | - | - | - |
| Amortization | - | 179.50 | 186.20 | 201.20 | 199.20 |
| Amortization Of Intangibles Income Statement | - | 179.50 | 186.20 | 201.20 | 199.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| The Cooper Companies, Inc.this co. | COO | $12.1B | 32.28↑ premium | 1.47 | 4.6% | 13.89 |
| Incyte Corporation | INCY | $20.2B | 15.72 | 3.91 | 24.9% | 9.75 |
| Viatris Inc. | VTRS | $18.5B | - | 1.26 | -23.9% | - |
| Zimmer Biomet Holdings, Inc. | ZBH | $16.8B | 23.79 | 1.32 | 5.6% | 10.69 |
| Solventum Corporation | SOLV | $14.3B |
| - |
| - |
| - |
| - |
| - |
| - |
| 9.17 |
| 2.83 |
| 30.8% |
| 7.23 |
| DaVita Inc. | DVA | $12.3B | 16.52 | -18.94 | -114.7% | 9.29 |
| Align Technology, Inc. | ALGN | $12.1B | 29.37 | 2.98 | 10.1% | 13.46 |
| Insulet Corporation | PODD | $10.1B | 41.04 | 6.69 | 16.3% | 21.20 |
| Universal Health Services, Inc. | UHS | $8.6B | 5.80 | 1.19 | 20.5% | 4.98 |
| Peer Median | - | 16.52 | 2.07 | 13.2% | 9.75 | |